CD1D and neoplasm: For Vδ2 T cells, approaches include using humanized anti-BTN3A antibodies to enhance their tumor-targeting ability (128, 129) or employing engineered tumor-γδ TCR bispecific antibodies (e.g., CD40, CD1D) to boost their cytotoxic efficiency (130, 131).